Developing new treatments for COVID-19
Official title: Clinical Development of COVID-19 Therapeutics
Funded at Aligos Therapeutics, INC. · NIH-11063909 · Data updated 2026-11-12
This study is looking for new treatments for COVID-19 that are specially designed for people with kidney and liver issues, and it gives patients a chance to join early trials to see how well these new options work for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aligos Therapeutics, INC. NIH-funded |
| Lab location | 1 site (South San Francisco, United States) |
| Project start | September 22, 2023 |
| Project end | February 15, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,300,776 |
| NIH project number | 75N93023C00052-P00001-9999-1 |
| Project ID | NIH-11063909 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include individuals with COVID-19 who also have renal or hepatic impairments.
✕Less likely to help
Patients without COVID-19 or those with no renal or hepatic impairments may not benefit from this research.
What this research studies
This research focuses on creating and testing new therapeutic options for COVID-19, particularly targeting patients with renal and hepatic impairments. The project involves several stages, including optimizing drug candidates, conducting preclinical studies, and eventually moving into Phase I clinical trials to assess safety and efficacy. Patients may have the opportunity to participate in early-stage trials that evaluate how well these new treatments work in their specific health conditions.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatments for COVID-19, particularly for patients with compromised kidney or liver function.
How similar studies have gone: Previous research has shown promise in developing antiviral therapies for COVID-19, making this approach both relevant and potentially impactful.
Where this research is happening
-
Aligos Therapeutics, INC.
South San Francisco, United States Active
Researchers
- Principal investigator: Wang, Stanley — Aligos Therapeutics, INC.
- Study coordinator: Wang, Stanley
Related research
Other NIH-funded projects on the same topics.
-
Structural factors linking minimum wage, COVID-19, and community violence
A long-term study will explore whether higher minimum wages and pandemic-related economic factors are connected to changes in violence in US communities.
-
COVID-19 healthcare disruptions and heart health inequities in NYC adults with multiple conditions
This project looks at how COVID-19-related gaps in care affected heart health in adults with several chronic conditions in New York City.
-
Modifying body fat to aid COVID-19 recovery through behavioral strategies
A study in veterans explores whether changing weight through lifestyle habits can improve recovery after COVID-19–related health problems.
-
Post-COVID Neuro-Cognitive Changes in Older African Americans
A study explores how COVID-19 affects thinking, memory, and daily life in older African American adults and what might be driving these changes.
-
How COVID school closures affected kids with or at risk for developmental differences
This NIH grant follows children aged 4 to 15 and their families to see how pandemic school closures impacted emotional well-being and parenting over three years.
-
Long-term COVID-19 effects in older Veterans and a rehabilitation approach
This project looks at how COVID-19 affects blood vessel health in older Veterans and tests a rehab strategy together with a mitochondria-targeted antioxidant to help recovery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.